The ESMO clinical practice guidelines for cancer prevention and screening in BRCA mutation carriers state that annual screening for pancreatic cancer may be considered in BRCA2 mutation carriers [36]. The gene discussed is BRCA2; the disease is pancreatic neoplasm.